Abstracts tagged "Nephritis and systemic lupus erythematosus (SLE)"

Abstract Number: 733 • 2018 ACR/ARHP Annual Meeting
Advanced Chronic Kidney Disease in Lupus Nephritis: Factors Leading to Progression
Konstantinos Tselios, Dafna D Gladman, Jiandong Su and Murray Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Advanced chronic kidney disease (CKD) carries an increased risk for progression to end-stage renal disease (ESRD) and renal replacement therapy. However, the rate of…
Abstract Number: 1100 • 2018 ACR/ARHP Annual Meeting
The Frequencies and Molecular Profiles of CD16+ Monocyte Subsets in Patients with Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome, and Antiphospholipid Syndrome with Lupus, Identify Specific Clinical Features of These Diseases
Chary Lopez-Pedrera¹, Maria Ángeles Aguirre Zamorano¹, Nuria Barbarroja², Patricia Ruiz-Limon³, Maria Carmen Abalos-Aguilera⁴, Yolanda Jiménez-Gómez², Ivan Arias de la Rosa⁴, Pedro Segui⁵, Rafaela Ortega-Castro², Eduardo Collantes Estevez¹, Alejandro Escudero-Contreras⁴, Lucas Le Lann⁶, Christophe Jamin⁶, Concepcion Marañón⁷, Marta Alarcón-Riquelme⁸, Jacques-Olivier Pers⁶ and Carlos Perez-Sanchez², ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain., Málaga, MA, Spain, ⁴Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵Radiology, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁶U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ⁷GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain, ⁸Medical Genomics, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: This study, developed within the IMI-JU project PRECISESADS framework, aimed to determine the enrichment on CD14+ and CD16+ monocyte subpopulations in SLE, APS and…
Abstract Number: 1708 • 2018 ACR/ARHP Annual Meeting
Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus
Min-Hua Tseng¹ and Jing-Long Huang², ¹Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Medicine, Chang-Gung University, Taoyuan city, Taiwan
Background/Purpose: Although aberrant complement activation is involved in the pathogenesis of systemic lupus erythematosus (SLE), the role of complement regulatory proteins in disease activity of…
Abstract Number: 1944 • 2018 ACR/ARHP Annual Meeting
Does Renin Angiotensin System Blockade in Addition to Immunosuppressive Therapy Improve Proteinuria in Acute Lupus Nephritis?
Konstantinos Tselios¹, Dafna D Gladman², Jiandong Su¹ and Murray Urowitz², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently recommended for patients with lupus nephritis (LN) as an adjunctive therapy for…
Abstract Number: 2646 • 2018 ACR/ARHP Annual Meeting
Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record
Wenlu Xiong¹, J.B. Boone¹, Cecilia P. Chung¹, Leslie Crofford² and April Barnado², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Antimalarials (AMs) improve survival in patients with systemic lupus erythematosus (SLE). Current guidelines suggest AMs for all SLE nephritis patients. Studies using patient-reported data…
Abstract Number: 793 • 2016 ACR/ARHP Annual Meeting
Multi-Parametric Model Development for Assessing Lupus Nephritis and Disease Activity
Christopher Sjöwall¹, Chelsea Bentow², Mary Ann Aure², Gabriella Lakos², Peter Martis² and Michael Mahler², ¹Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ²Research and Development, Inova Diagnostics, San Diego, CA
Multi-parametric model development for assessing lupus nephritis and disease activity Christopher Sjӧwall1, Chelsea Bentow2, Mary Ann Aure2, Gabriella Lakos2, Peter Martis2, Michael Mahler2 1AIR/Rheumatology, Department…
Abstract Number: 716 • 2015 ACR/ARHP Annual Meeting
Urinary Proteomics Identifies Three Novel Biomarkers for Lupus Nephritis Activity: Retinol Binding Protein, Alpha-1-Antichymotrysin and Haptoglobin
Amita Aggarwal¹, Sudhir sinha², Ranjan Gupta³, Liza Rajasekhar⁴, Akhilesh Yadav³, Ramnath Misra¹ and Virsingh Negi⁵, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, ³Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁴Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, ⁵Department of Clinical Immunology, JIPMER, Puducherry, India
Background/Purpose: Urinary biomarkers have a potential for identification, follow-up and assessment of response to treatment in patients with lupus nephritis. Urinary proteomics can help in…
Abstract Number: 1772 • 2015 ACR/ARHP Annual Meeting
Anti-Pentraxin 3 Antibodies Ameliorate Disease Manifestations and Lupus-like Nephritis in New Zealand Black/New Zealand White F1 Mice
Mariele Gatto¹, Nicola Bassi¹, Anna Ghirardello¹, Roberto Luisetto¹, Silvano Bettio¹, Luca Iaccarino¹, Leonardo Punzi² and Andrea Doria², ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose: Pentraxin 3 (PTX3) is an acute-phase protein released by different cell types including renal epithelial cells and immune-competent cells. PTX3 is able to either…
Abstract Number: 1791 • 2015 ACR/ARHP Annual Meeting
Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events? a Case-Control Study
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently used as an adjuvant treatment in lupus nephritis (LN) patients for the…
Abstract Number: 2076 • 2015 ACR/ARHP Annual Meeting
Development of Lupus Nephritis: Preclinical Evaluation of Patients Who Subsequently Develop Systemic Lupus Erythematosus Demonstrate Elevation of Select Soluble Mediators Prior to and at Disease Classification in Patients with Nephritis
Melissa E. Munroe¹, Jourdan R. Anderson¹, Julie M. Robertson¹, Timothy B. Niewold², George C. Tsokos³, Michael P. Keith⁴, Joan T. Merrill⁵, Jill P. Buyon⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁷Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a heterogeneous autoimmune disease marked by immune dysregulation and a spectrum of pathogenic autoantibodies. Why some patients have only moderate symptoms and…
Abstract Number: 2787 • 2014 ACR/ARHP Annual Meeting
Identification of Urinary Biomarkers for Lupus Nephritis
Carolina Landolt-Marticorena¹, Stephenie Prokopec², Heather Reich³, James Scholey⁴, Carmen Avila-Casado⁵, Paul R. Fortin⁶, Paul Boutros² and Joan Wither⁷, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Nephrology, University Health Network, Toronto, ON, Canada, ⁴Department of Medicine, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Pathology, University Health Network, Toronto, ON, Canada, ⁶Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ⁷Immunology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is a major determinant of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Variability in clinical course, underlying renal injury, and…
Abstract Number: 1939 • 2014 ACR/ARHP Annual Meeting
Development of Cell–Based Enzyme–Linked Immunosorbent Assay for the Quantification of Anti–M–type phospholipase–a–receptor Antibodies and Its Clinical Usefulness in Patients with Membranous Nephropathy
Yasuhiro Katsumata¹, Yuko Okamoto¹, Takahito Moriyama², Manabu Kawamoto¹, Hirotaka Kaneko¹, Yasushi Kawaguchi¹, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹, Keiko Uchida², Kosaku Nitta² and Hisashi Yamanaka³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose : Better risk prediction is needed to identify patients who will benefit from immunosuppressive therapy with idiopathic membranous nephropathy (MN) due to the variable…
Abstract Number: 1656 • 2014 ACR/ARHP Annual Meeting
Rate of Histological Transformation to Higher Grade Nephritis in Class II Mesangial Proliferative Lupus Glomerulonephritis
Andrea Zacarias¹, Javier Narváez², Gloria Albert¹, Milagros Ricse¹, Paula Estrada¹, Melany Pestaña³, Chema Mora³, Jesus Rodriguez Moreno¹, Xavier Fulladosa⁴, Manel Rubio Rivas³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Class II mesangial proliferative lupus nephritis has generally been considered a mild form of the condition, with a good response to glucocorticoid treatment. However,…
Abstract Number: 1655 • 2014 ACR/ARHP Annual Meeting
Lupus Nephritis: Clinicopathological Correlation in 126 Biopsies
Milagros Ricse¹, Javier Narváez², Gloria Albert¹, Paula Estrada¹, Helena Borrell¹, Eugenia de Lama³, Xavier Fulladosa⁴, Manel Rubio Rivas⁵, Olga Capdevila⁵, Francesca Mitjavila⁵, Xavier Juanola⁶ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Radiology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To analyze the correlation between clinical and laboratory data and type of histological injury in a cohort of patients with lupus nephritis (LN). Methods:…
Abstract Number: 1659 • 2014 ACR/ARHP Annual Meeting
The Clinical Relevance of a Repeat Biopsy in Lupus Nephritis (LN) Flares
Milagros Ricse¹, Javier Narváez², Gloria Albert¹, Paula Estrada¹, Sergi Heredia¹, Andrea Zacarias¹, Helena Borrell¹, Eulalia Armengol¹, Xavier Fulladosa³, Joan Torras³, Olga Capdevila⁴, Francesca Mitjavila⁴ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Renal biopsy is the gold standard for assessing renal activity and hence guiding treatment. Whether a repeat renal biopsy is helpful during flares of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].